MX368063B - Compuestos de benzopirano funcionalizados y uso de los mismos. - Google Patents

Compuestos de benzopirano funcionalizados y uso de los mismos.

Info

Publication number
MX368063B
MX368063B MX2016010137A MX2016010137A MX368063B MX 368063 B MX368063 B MX 368063B MX 2016010137 A MX2016010137 A MX 2016010137A MX 2016010137 A MX2016010137 A MX 2016010137A MX 368063 B MX368063 B MX 368063B
Authority
MX
Mexico
Prior art keywords
functionalised
benzopyran compounds
present
cancer
compounds
Prior art date
Application number
MX2016010137A
Other languages
English (en)
Other versions
MX2016010137A (es
Inventor
Heaton Andrew
Brown David
Kelly Graham
Original Assignee
Novogen ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novogen ltd filed Critical Novogen ltd
Publication of MX2016010137A publication Critical patent/MX2016010137A/es
Publication of MX368063B publication Critical patent/MX368063B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere ampliamente a agentes anticáncer. En particular, la presente invención se refiere a compuestos de benzopirano seleccionados, la preparación de los mismos, y su uso en métodos para tratar un cáncer y reducir la incidencia o riesgo de recurrencia del cáncer.
MX2016010137A 2014-02-07 2015-02-05 Compuestos de benzopirano funcionalizados y uso de los mismos. MX368063B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461937368P 2014-02-07 2014-02-07
US201461987323P 2014-05-01 2014-05-01
PCT/AU2015/050040 WO2015117202A1 (en) 2014-02-07 2015-02-05 Functionalised benzopyran compounds and use thereof

Publications (2)

Publication Number Publication Date
MX2016010137A MX2016010137A (es) 2017-02-15
MX368063B true MX368063B (es) 2019-09-18

Family

ID=53777071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010137A MX368063B (es) 2014-02-07 2015-02-05 Compuestos de benzopirano funcionalizados y uso de los mismos.

Country Status (25)

Country Link
US (2) US9701655B2 (es)
EP (1) EP2953938B1 (es)
JP (1) JP6570042B2 (es)
KR (1) KR102395543B1 (es)
CN (2) CN105980372B (es)
AU (1) AU2015213484B2 (es)
BR (1) BR112016018099B8 (es)
CA (1) CA2936012C (es)
CL (1) CL2016001937A1 (es)
DK (1) DK2953938T3 (es)
ES (1) ES2643407T3 (es)
HK (1) HK1218914A1 (es)
IL (1) IL241515B (es)
LT (1) LT2953938T (es)
MX (1) MX368063B (es)
MY (1) MY195739A (es)
NZ (1) NZ711603A (es)
PH (1) PH12016501422B1 (es)
PL (1) PL2953938T3 (es)
PT (1) PT2953938T (es)
RU (1) RU2676766C2 (es)
SA (1) SA516371583B1 (es)
SG (2) SG11201604490SA (es)
SI (1) SI2953938T1 (es)
WO (1) WO2015117202A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2953938T (pt) * 2014-02-07 2017-10-09 Novogen ltd Compostos de benzopirano funcionais e sua utilização
PL3253208T3 (pl) 2015-02-02 2021-11-08 Mei Pharma, Inc. Terapie kombinowane do zastosowania w leczeniu nowotworu piersi
US10265294B2 (en) * 2016-03-31 2019-04-23 Yale University Compositions and methods for treating epithelial cancer
US11559510B2 (en) 2016-04-06 2023-01-24 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
EP3439642A4 (en) * 2016-04-06 2019-11-13 Noxopharm Limited IMPROVEMENTS IN RADIATION THERAPY
CN109700794B (zh) * 2017-03-01 2021-01-08 浙江大学 腙结构类型雄激素受体拮抗剂及其应用
AU2021247415A1 (en) 2020-03-30 2022-09-29 Noxopharm Limited Methods for the treatment of inflammation associated with infection
WO2023235929A1 (en) * 2022-06-08 2023-12-14 Noxopharm Limited Functionalised benzopyran compounds and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US4447622A (en) 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof
BE891562A (fr) 1981-12-21 1982-04-16 Council Scient Ind Res Isomeres 1 et d de d1-3, 4-trans-3, 4-diarylchromanes 2, 2-disubstitues et leurs derives, leur preparation et leur utilisation
US5451603A (en) 1993-03-11 1995-09-19 Zymogenetics, Inc. 3,4-diarylchromans for treatment of dermatitis
US5280040A (en) 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
BR9606754A (pt) 1995-01-13 1998-01-06 Novo Nordisk As Uso de compostos processo para tratamento e profilaxia de ginecomastia idiopática ou fisiológia e novo detalhe característico ou combinação de detalhes
HUP9702244A3 (en) 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders
CN1168098A (zh) 1995-01-13 1997-12-17 诺沃挪第克公司 3,4-二苯基苯并二氢吡喃在生产用于治疗或预防高脂蛋白血症、高甘油三酯血症、高脂血症或高胆固醇血症或动脉硬化或用于抗凝治疗的药物组合物中的用途
WO1996022093A1 (en) 1995-01-20 1996-07-25 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis
TW448046B (en) 1995-01-20 2001-08-01 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
HUP9702246A3 (en) 1995-01-20 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of degenerative cerebral disorders
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
KR19990077156A (ko) 1996-01-11 1999-10-25 한센 핀 베네드, 안네 제헤르 폐경기 증상의 치료 또는 예방을 위한 약학적 조성물의제조를 위한 3,4-디페닐크로만의 사용
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
CN1207038A (zh) 1996-01-11 1999-02-03 诺沃挪第克公司 3,4－二苯基苯并二氢吡喃在生产预防或治疗绝经症状的药物组合物中的应用
US5756539A (en) 1996-07-11 1998-05-26 Novo Nordis A/S 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders
US5780502A (en) 1996-07-12 1998-07-14 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
US5919817A (en) 1996-10-28 1999-07-06 Novo Nordisk A/S Cis-3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
AU4700097A (en) * 1996-10-28 1998-05-22 Novo Nordisk A/S Novel (cis)-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US6043269A (en) 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
IL129625A0 (en) 1996-10-28 2000-02-29 Novo Nordisk As Novel (-)-enantionmers of CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US5925771A (en) 1996-10-28 1999-07-20 Novo Nordisk A/S Process for the preparation of (-)-3,4-trans-diarylchromans
WO1998033499A1 (en) 1997-01-29 1998-08-06 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for increasing libido in post-menopausal women
AU5550398A (en) 1997-01-29 1998-08-25 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical compositionfor inhibiting senescence-associated motor impairment
US6184005B1 (en) 1998-04-28 2001-02-06 Novo Nordisk A/S Enzymatic resolvation for obtaining a (−)-3,4-trans-diarylchroman
ATE466850T1 (de) * 1998-09-23 2010-05-15 Res Dev Foundation Tocopherole, tocotrienole, sonstige chroman- und seitenkettenderivate, sowie deren verwendungen
AU6315300A (en) 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
US7226945B2 (en) 2000-10-13 2007-06-05 Astrazeneca Ab Estrogen receptor-β ligands
WO2002074307A1 (en) 2001-03-16 2002-09-26 Novogen Research Pty Ltd Treatment of restenosis
US20050119301A1 (en) 2001-03-16 2005-06-02 Alan Husband Treatment of restenosis
JP2005524630A (ja) 2002-01-14 2005-08-18 ノルディック・ビオサイエンス・エー／エス エストロゲン受容体を介する軟骨破壊の抑制
US20040167165A1 (en) 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-7 receptor
WO2004108944A1 (ja) 2003-06-04 2004-12-16 Mitsubishi Gas Chemical Company, Inc. 光学活性クロマンカルボン酸エステルの製造方法
WO2005049008A1 (en) * 2003-11-19 2005-06-02 Novogen Research Pty Ltd Combinational radiotherapy and chemotherapy compositions and methods
JP4976649B2 (ja) * 2004-09-21 2012-07-18 マーシャル エドワーズ，インク． 化合物
ES2516067T3 (es) * 2004-09-21 2014-10-30 Mei Pharma, Inc. Derivados de cromano sustituidos, medicamentos y utilización en terapia
AU2005287865B2 (en) 2004-09-21 2012-02-16 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy
EP1809618B1 (en) * 2004-09-21 2013-07-17 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US7528267B2 (en) 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
AU2007217529A1 (en) 2006-02-21 2007-08-30 Trigen Limited Heterocyclic compounds and their use in the treatment of cardiovascular disease
CA2668008A1 (en) 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
CN101210012B (zh) 2006-12-31 2011-09-14 南华大学 新的含烟酸异黄酮酯衍生物及其制造方法和用途
US20120039917A1 (en) 2008-08-29 2012-02-16 Alan James Husband Immunomodulating activities
US20100130598A1 (en) 2008-10-22 2010-05-27 Novogen Research Pty Ltd. Methods for inducing programmed cell death
AU2008230055A1 (en) 2008-10-22 2010-05-06 Novogen Research Pty Ltd Methods for Inducing Programmed Cell Death
EP2548017A2 (en) 2010-03-15 2013-01-23 Genus Oncology, Llc Small molecule inhibitors of muc1 and methods of identifying the same
WO2011156889A1 (en) 2010-06-14 2011-12-22 Trt Pharma Inc. Novel modulators of nrf2 and uses thereof
EP2635121B1 (en) * 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
CN102153535A (zh) 2011-03-04 2011-08-17 中国海洋大学 一种抗肿瘤多药耐药抑制剂苯并吡喃-3-醇酯化衍生物及其制备方法和应用
US20120251630A1 (en) 2011-03-29 2012-10-04 Marshall Edwards, Inc. Remission therapy of cancer with isoflavonoids
US20150018566A1 (en) * 2011-08-25 2015-01-15 The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy Tubulin binding agents
AU2013271731A1 (en) 2012-06-07 2014-12-18 Georgia State University Research Foundation, Inc. SecA inhibitors and methods of making and using thereof
CN103408528B (zh) 2013-08-13 2015-04-29 浙江大学 一种色满化合物及其制备方法和应用
CN103450142B (zh) 2013-09-04 2015-03-25 浙江大学 一种色满化合物及其提取方法和应用
CN103585145A (zh) 2013-11-28 2014-02-19 常州科立信医疗器械有限公司 Artoxanthochromane在治疗前列腺癌药物中的应用
CN103690525A (zh) 2013-12-02 2014-04-02 常州科立信医疗器械有限公司 Artoxanthochromane在治疗舌癌药物中的应用
CN103638008B (zh) 2013-12-02 2015-09-16 刘艳娇 Artoxanthochromane在治疗皮肤癌药物中的应用
CN103705503A (zh) 2013-12-04 2014-04-09 常州科立信医疗器械有限公司 Artoxanthochromane在治疗乳腺癌药物中的应用
PT2953938T (pt) * 2014-02-07 2017-10-09 Novogen ltd Compostos de benzopirano funcionais e sua utilização

Also Published As

Publication number Publication date
IL241515A0 (en) 2015-11-30
MX2016010137A (es) 2017-02-15
CA2936012A1 (en) 2015-08-13
JP6570042B2 (ja) 2019-09-04
LT2953938T (lt) 2017-10-10
CL2016001937A1 (es) 2017-01-20
US9701655B2 (en) 2017-07-11
PL2953938T3 (pl) 2017-12-29
JP2017507175A (ja) 2017-03-16
MY195739A (en) 2023-02-08
RU2016133731A3 (es) 2018-08-08
CN108484559A (zh) 2018-09-04
WO2015117202A1 (en) 2015-08-13
RU2676766C2 (ru) 2019-01-11
AU2015213484A1 (en) 2015-09-17
PH12016501422A1 (en) 2016-08-31
SG11201506988TA (en) 2015-10-29
PT2953938T (pt) 2017-10-09
NZ711603A (en) 2017-05-26
CN105980372A (zh) 2016-09-28
US20160340329A1 (en) 2016-11-24
KR102395543B1 (ko) 2022-05-09
BR112016018099A2 (pt) 2017-08-08
AU2015213484B2 (en) 2015-11-05
BR112016018099B1 (pt) 2022-10-11
SG11201604490SA (en) 2016-07-28
SA516371583B1 (ar) 2019-04-18
RU2016133731A (ru) 2018-03-12
EP2953938A4 (en) 2016-08-10
HK1218914A1 (zh) 2017-03-17
IL241515B (en) 2019-06-30
KR20160110427A (ko) 2016-09-21
EP2953938B1 (en) 2017-08-02
ES2643407T3 (es) 2017-11-22
EP2953938A1 (en) 2015-12-16
BR112016018099B8 (pt) 2023-01-17
CA2936012C (en) 2023-03-07
CN105980372B (zh) 2018-05-08
SI2953938T1 (en) 2018-01-31
US10370349B2 (en) 2019-08-06
PH12016501422B1 (en) 2016-08-31
US20180141925A1 (en) 2018-05-24
DK2953938T3 (en) 2017-10-02

Similar Documents

Publication Publication Date Title
HK1249524A1 (zh) 用於治療血載癌症的免疫檢查點抑制劑
PH12016501422A1 (en) Functionalised benzopyran compounds and use thereof
EP3166640A4 (en) Combination therapy compositions and methods for treating cancers
NZ731467A (en) Anti-tim3 antibodies and methods of use
TW201613648A (en) Compounds and compositions for immunotherapy
MA39906A (fr) Polythérapies pour le traitement du cancer
EP3222278A4 (en) Use of azelnidipine in preparing medicinal composition for treating cancers
IL253979A0 (en) Methods, preparations and kits for cancer treatment
EP3169363A4 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
MX2016016881A (es) Anticuerpos que se unen a axl.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
EP3200815A4 (en) Methods and compositions for treating cancer
IL276733A (en) Use of Aribolin in cancer treatment
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
EP3169333A4 (en) Methods and compositions for enhancing cancer therapy
PH12016501838A1 (en) Compounds and their methods of use
MX2017009608A (es) Compuestos anticancerigenos.
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
EP3160591A4 (en) Compositions and methods for treating cancer
GB2546703A (en) Compounds
ZA201403006B (en) Composition for use in treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration